Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
88 hedge funds and large institutions have $79.4M invested in Antares Pharma, Inc. in 2015 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 22 reducing their positions, and 14 closing their positions.
1,067% more call options, than puts
Call options by funds: $105K | Put options by funds: $9K
64% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 90 → 88 (-2)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
31% less capital invested
Capital invested by funds: $114M → $79.4M (-$35.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$6.87M |
| 2 |
BC
Broadfin Capital
New York
|
+$4.18M |
| 3 |
Millennium Management
New York
|
+$2.53M |
| 4 |
Renaissance Technologies
New York
|
+$1.53M |
| 5 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$800K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$16M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.73M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$1.23M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$433K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$340K |
ATRS Hedge Fund Activity: Q4 2015 in Review
88 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2015, worth a combined $79.4M — down 31% from $114M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ATRS and 12 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 36 added.
The largest buyer was Armistice Capital, adding an estimated $6.87M. The largest seller was Deerfield Management, cutting an estimated $16M.
- 88 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2015, down from 90 in Q3 2015.
- Funds reported $79.4M of Antares Pharma, Inc. stock for Q4 2015, down 31% quarter-over-quarter.
- 12 funds opened new Antares Pharma, Inc. positions in Q4 2015 and 14 closed out, a net change of -2 holders.
- The largest Antares Pharma, Inc. buyer in Q4 2015 was Armistice Capital, an estimated $6.87M added.
- The largest Antares Pharma, Inc. seller in Q4 2015 was Deerfield Management, an estimated $16M sold.
Based on aggregated 13F filings for Q4 2015.